Please login to the form below

Not currently logged in
Email:
Password:

Dendreon CEO to step down

John Johnson to leave next summer as Provenge sales stall

Dendreon has announced that CEO John Johnson will leave the company in August next year.

The decision comes as Dendreon continues to struggle as its only product Provenge – a 'vaccine' for prostate cancer ' – fails to live up to high expectations.

According to the company's financial report, sales of Provenge declined from $325m in 2012 to $286m in 2013. This led to Dendreon dropping out the top 25 companies working in oncology.

These poor sales meant the company reported operating losses of around $300m and major job cuts.

On leaving, Johnston said: "I first joined Dendreon because of my admiration for the company as a pioneer in immunotherapy and because of my belief in the power of Provenge as a personalised cancer treatment. That belief still holds true today.”

11th June 2014

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics